Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts. [PDF]
Front OncolWang Y, Jin S.
europepmc +1 more source
Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm. [PDF]
Cancer MedYoon H +13 more
europepmc +1 more source
Are Myeloproliferative NeoplasmsâUnclassifiable Really Unclassifiable?
eJHaemGiovanni Barosi +2 more
doaj +1 more source
Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study. [PDF]
Br J HaematolBatyrbekova N +6 more
europepmc +1 more source
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML [PDF]
, 2013 et al,, Oh, Stephen T
core +2 more sources
TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. [PDF]
Eur J HaematolChen D, Cantu M, Siddon A, Weinberg OK.
europepmc +1 more source
Latent JAK2 V617F-Positive Myeloproliferative Neoplasm With Normal Blood Counts and Recurrent Splanchnic Vein Thrombosis in a Young Woman. [PDF]
CureusThida AM +4 more
europepmc +1 more source
Differential regulation of mTORC2 signalling by type I and type II calreticulin (CALR) driver mutations of myeloproliferative neoplasm. [PDF]
Cell Commun SignalNaseer S +6 more
europepmc +1 more source
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm. [PDF]
Curr Oncol RepSingh S, Peshin S, Larsen A, Gowin K.
europepmc +1 more source
Monoclonal gammopathy and myeloproliferative neoplasm molecular diagnostics
Hematology, Transfusion and Cell TherapyStephen E. Langabeer
doaj +1 more source